Trial Profile
A Phase II Trial of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (MPM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Fresolimumab (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 May 2010 New trial record